Interesting comments from Block - we should really see a decent jump if and when Abaxis lands a major UCC Piccolo deal. The change of sales strategy is for the long term, but I would like to see extra sales people picking up Piccolo enquiries to improve sales and morale

Sounds as though sales other than Piccolo have held up well, and with the heart worm test boosting sales Q3, we should see revenue and bottom line growth.

When you consider the price of some companies that have never traded at a profit, ABAX is still great value - EPS of $0.70 and about $80 million cash, the current stock price offers great upside potential if they can clinch a few deals.

Those LT holders will remember the days when we thought ABAX was never going to break even, and the doubting Thomas' lost out. In the next few days we may have a few more lemmings bail out, so take advantage of the stock price while you can.